Nexag (Tranexamic Acid)

Tranexamic acid blocks the conversion of plasminogen to plasmin, the enzyme responsible for breaking down fibrin clots. By inhibiting plasmin formation, the drug preserves the fibrin matrix of clots, making them more resistant to dissolution and thereby reducing ongoing bleeding.

The dosage of Nexag is determined by the prescribing clinician based on the specific indication, patient age, weight, renal function, and overall clinical situation. Healthcare providers follow local guidelines and adjust the regimen to achieve optimal hemostasis while minimizing risk.

Safety data for tranexamic acid in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when possible. The decision to use Nexag during pregnancy or breastfeeding should be made by a qualified healthcare professional.

To request Nexag, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nexag (tranexamic acid) is a synthetic lysine analogue that directly inhibits plasminogen activation, whereas other agents such as epsilon‑aminocaproic acid have a similar mechanism but lower potency. Compared with newer agents like aprotinin, tranexamic acid offers a favorable safety profile and is more widely used in diverse bleeding scenarios.

Nexag should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture and direct sunlight to maintain product stability throughout its shelf life.

Nexag is supplied as an oral tablet and is taken by mouth with water. The exact timing relative to the bleeding event or surgical procedure is determined by the prescriber, who may advise dosing before, during, or after the anticipated bleeding risk.

The most serious risks include the potential for thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, especially in patients with pre‑existing clotting disorders. Rare but severe reactions can involve visual disturbances, severe allergic responses, hypotension, and seizures.

Nexag is contraindicated in patients with active intravascular clotting, known hypersensitivity to tranexamic acid, or those receiving thrombolytic therapy. Caution is also advised for individuals with severe renal impairment or a history of thromboembolic disease.